1-12 of 12
Rimas J. Orentas, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Paolo F Caimi, MD, Ashish Sharma, Patricio Rojas, MD, Seema Patel, PharmD, Jane Reese, Folashade Otegbeye, MBBChir,MPH, Andrew Worden, Michael Kadan, Michael Maschan, MD PhD, Rimas J Orentas, PhD, Boro Dropulic, PhDMBA, Rafick Sekaly, Marcos de Lima, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-143114
Published: 2020
Journal Articles

CD22 CAR-T Induces Both CD19 and CD22 Surface Down-Modulation: Defining a Mechanism of Generalized Immune Evasion and the Effects of Epigenetic Modifiers

Lingyan Wang, PhDDVM, Yue Zhang, MS, Eden Anderson, BS, Rajesh Kumar, PhD, Adam J. Lamble, MD, Rimas J Orentas, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-134930
Published: 2020
Journal Articles

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Fenlu Zhu, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Walter L. Longo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Boro Dropulic, PhD, Rimas J Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4465.
https://doi.org/10.1182/blood-2019-125328
Published: 2019
Journal Articles

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Brakke, MS, Stephanie Rhea, BS, Roxana Hicks, BS, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, PhD, Daniel Li, PhD, Michael C. Jensen, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4022.
https://doi.org/10.1182/blood-2018-99-117493
Published: 2018
Journal Articles

CD22-Targeted Chimeric Antigen Receptor (CAR) T Cells Containing The 4-1BB Costimulatory Domain Demonstrate Enhanced Persistence and Superior Efficacy Against B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Compared To Those Containing CD28

Waleed Haso, M.S, Haiying Qin, MS, Ling Zhang, Rimas J Orentas, PhD, Terry J Fry, MD
Journal: Blood
Blood (2013) 122 (21): 1431.
https://doi.org/10.1182/blood.V122.21.1431.1431
Published: 2013
Journal Articles

Pre-Clinical Development Of a Novel Chimerical Antigen Receptor Targeting High-Risk Pediatric ALL Over-Expressing Tslpr

Haying Qin, Cho Monica, Waleed Haso, M.S., Ling Zhang, David M. Barrett, MD/PhD, Rimas J Orentas, PhD, Stephan A. Grupp, MD, PhD, Terry J Fry, MD
Journal: Blood
Blood (2013) 122 (21): 2665.
https://doi.org/10.1182/blood.V122.21.2665.2665
Published: 2013
Journal Articles

Synthetic Chimeric Antigen Receptors (CARs) Rapidly Induce Exhaustion and Augmented Glycolytic Metabolism In Human T Cells and Implicate Persistent CD28 Signaling As a Driver Of Exhaustion In Human T Cells

Adrienne H. Long, Rimas J. Orentas, PhD, Crystal L. Mackall, MD
Journal: Blood
Blood (2013) 122 (21): 192.
https://doi.org/10.1182/blood.V122.21.192.192
Published: 2013
Journal Articles

A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.

Waleed Haso, M.S., Daniel W. Lee, III, MD, Ira Pastan, MD, Dimiter S. Dimitrov, Ph.D, Crystal L Mackall, MD, Rimas J Orentas, PhD
Journal: Blood
Blood (2012) 120 (21): 2611.
https://doi.org/10.1182/blood.V120.21.2611.2611
Published: 2012
Journal Articles

Generation and Optimization of a Chimeric Antigen Receptor Against CD22: A New Immunotherapeutic Agent for Treating B Lineage Leukemia and Lymphoma

Rimas J Orentas, PhD, Waleed Haso, B.S., Richard A. Morgan, Ira Pastan, MD, Crystal L Mackall, MD
Journal: Blood
Blood (2011) 118 (21): 4313.
https://doi.org/10.1182/blood.V118.21.4313.4313
Published: 2011
Journal Articles

ALL Xenografts Reveal the Importance of Anti-CD19-Chimeric Antigen Receptor Cell Dose, Cell Persistence and Surprising Antitumor Activity of CD4+ Anti-CD19-CAR T Cells in Eradicating Pediatric Acute Lymphocytic Leukemia In Vivo

Daniel W. Lee, III, MD, James N Kochenderfer, Rimas J Orentas, PhD, Elizabeth G. Gardner, B.S., Crystal L Mackall, MD
Journal: Blood
Blood (2011) 118 (21): 574.
https://doi.org/10.1182/blood.V118.21.574.574
Published: 2011
Journal Articles

4-1BBL-Expressing aAPCs Attenuate IL-15-Induced NK Cell Expansion and Cytokine Production In Vitro but Induce NK Cell-Mediated Gvhd In Vivo

Christian M. Capitini, MD, Joanna L. Meadors, BS, Monica M. Cho, Rimas J. Orentas, PhD, Crystal L. Mackall, MD, Terry J. Fry, MD
Journal: Blood
Blood (2010) 116 (21): 2536.
https://doi.org/10.1182/blood.V116.21.2536.2536
Published: 2010
Journal Articles

Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor

Daniel W. Lee, MD, James N Kochenderfer, Christoph Rader, PhD, Rimas J Orentas, PhD, Crystal L Mackall, MD
Journal: Blood
Blood (2010) 116 (21): 3262.
https://doi.org/10.1182/blood.V116.21.3262.3262
Published: 2010